KeChow Pharma’s Keluping, First NRAS Mutant Melanoma Therapy, Hits the Market
Shanghai-based KeChow Pharma has announced the official market launch of its groundbreaking drug, Keluping (tunlametinib),...
KeChow Pharma
KeChow Pharma Secures Conditional Approval for HL-085, a First-of-Its-Kind MEK Inhibitor for Advanced Melanoma
Shanghai-based KeChow Pharma has received conditional marketing approval from the National Medical Products Administration (NMPA)...
CDE Grants Priority Review Status to Kechow’s HL-085 for Melanoma Treatment
The Center for Drug Evaluation (CDE) website indicates that Kechow Pharma’s HL-085 is set to...